A Survey of Maribavir Tablets in Participants with Cytomegalovirus Infection

Last updated: September 17, 2024
Sponsor: Takeda
Overall Status: Active - Recruiting

Phase

N/A

Condition

Cytomegalovirus Infections

Treatment

Maribavir

Clinical Study ID

NCT06577363
TAK-620-4013
jRCT2031240302
  • All Genders

Study Summary

This study is a survey in Japan of Maribavir tablets used to treat participants with Cytomegalovirus (CMV) infection refractory to existing anti-CMV therapy in organ transplantation (including hematopoietic stem cell transplantation).

The main aim of the study is to check if treatment with Maribavir can protect Japanese people against CMV infection, and to check side effect from the study treatment. The study sponsor will not be involved in how the participants are treated but will provide instructions on how the clinics will record what happens during the study.

During the study, participants with CMV infection will take Maribavir tablets according to their clinic's standard practice. The study doctors will check for side effects from Maribavir tablets for 27 weeks.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • All participants with Cytomegalovirus (CMV) infection refractory to existinganti-CMV therapy in organ transplantation (including hematopoietic stem celltransplantation).

Exclusion

Exclusion Criteria:

  • None

Study Design

Total Participants: 250
Treatment Group(s): 1
Primary Treatment: Maribavir
Phase:
Study Start date:
August 28, 2024
Estimated Completion Date:
August 30, 2031

Connect with a study center

  • Takeda selected site

    Tokyo,
    Japan

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.